Trends of endometrial cancer incidence from 2000 to 2015 in the United States.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 5591-5591
Author(s):  
V V Pavan Kedar Mukthinuthalapati ◽  
Muhammad Zain Farooq ◽  
Shweta Gupta

5591 Background: Recent studies have shown that obesity related cancers are increasing in incidence in the US as the rates of obesity rise and some cancers, like colorectal cancer, are occurring in younger age groups. We studied trends in incidence of endometrial cancer (EC), one of the obesity related cancers, in a population wide analysis. Methods: We analyzed data from all cases of EC between 2000 and 2015 from 18 US cancer registries using the National Cancer Institute’s Surveillance, Epidemiology and End Results Program. SEER*Stat was used to query the database for annual percent changes (APC), incidence ratios and percent change in incidence across different age groups, years of diagnosis, histologic subtypes, grade and race. We also studied the reported rates and trends of obesity in the US. Results: APC of age-adjusted EC incidence between 2000 and 2015 was +0.9% (95% confidence interval (CI) 1.1-0.6, p value<0.05). Incidence of EC rose from 17.8 per 100,000 to 19.7 per 100,000 during the same duration. APC for EC incidence for age groups 20-39 and >40 were +3.2% (p-value <0.05) and +0.8% (p value <0.05), respectively. For the age-group 20-39, endometrioid EC was the only histologic subtype that rose in incidence, with an APC of +5.5% and absolute percentage change of 156%. The APC of EC in 20-39 age group was more for whites (3.5%, p-value<0.05) and Asians (2.2%, p-value<0.05) than blacks (1.8, p-value <0.05). CDC reported an increase in obesity rates in adults from 30.5% in 2000 to 37.7% in 2014. Table shows trends of EC incidence in age groups 20-39 and >40 years across various histologic subtypes. (Abbreviations: S significant, NS not significant, NC non-calculable). Conclusions: Endometrial cancer, especially of endometrioid histology, is increasing in incidence and is occurring more often in the younger population. The concomitant rise in obesity rates during the same period point towards a possible causality of the increased in incidence of EC. Population based strategies are needed to decrease the trends in obesity so as to decrease the risk of endometrial cancer in younger women. [Table: see text]

Author(s):  
Ana Cristina Viana Campos ◽  
Efigênia Ferreira e Ferreira ◽  
Andréa Maria Duarte Vargas ◽  
Lúcia Hisako Takase Gonçalves

ABSTRACT Objective: to identify the healthy aging profile in octogenarians in Brazil. Method: this population-based epidemiological study was conducted using household interviews of 335 octogenarians in a Brazilian municipality. The decision-tree model was used to assess the healthy aging profile in relation to the socioeconomic characteristics evaluated at baseline. All of the tests used a p-value < 0.05. Results: the majority of the 335 participating older adults were women (62.1%), were aged between 80 and 84 years (50.4%), were widowed (53.4%), were illiterate (59.1%), had a monthly income of less than one minimum wage (59.1%), were retired (85.7%), lived with their spouse (63.8%), did not have a caregiver (60.3%), had two or more children (82.7%), and had two or more grandchildren (78.8%). The results indicate three age groups with a healthier aging profile: older adults aged 80 to 84 years (55.6%), older adults aged 85 years and older who are married (64.9%), and older adults aged 85 and older who do not have a partner or a caregiver (54.2%). Conclusion: the healthy aging profile of octogenarians can be explained by age group, marital status, and the presence of a caregiver.


Author(s):  
Marie-Josèphe Horner ◽  
Meredith S Shiels ◽  
Ruth M Pfeiffer ◽  
Eric A Engels

Abstract Background Antiretroviral therapy (ART) has reduced mortality among people living with human immunodeficiency virus (HIV), but cancer remains an important cause of death. We characterized cancer-attributable mortality in the HIV population during 2001–2015. Methods We used data from population-based HIV and cancer registries in the United States (US). Cox proportional hazards regression models were used to estimate adjusted hazard ratios (HRs) associating cancer diagnoses with overall mortality, we could perhaps cut these words to accommodate the word limit. However readers will probably want to know what statistical adjustments were made to the model. Population-attributable fractions (PAFs) were calculated using these HRs and the proportion of deaths preceded by cancer. Cancer-specific PAFs and cancer-attributable mortality rates were calculated for demographic subgroups, AIDS-defining cancers (Kaposi sarcoma [KS], non-Hodgkin lymphoma [NHL], cervical cancer), and non–AIDS-defining cancers. Results Cancer-attributable mortality was 386.9 per 100 000 person-years, with 9.2% and 5.0% of deaths attributed to non–AIDS-defining and AIDS-defining cancers, respectively. Leading cancer-attributable deaths were from NHL (3.5%), lung cancer (2.4%), KS (1.3%), liver cancer (1.1%), and anal cancer (0.6%). Overall, cancer-attributable mortality declined from 484.0 per 100 000 person-years during 2001–2005 to 313.6 per 100 000 person-years during 2011–2015, while the PAF increased from 12.6% to 17.1%; the PAF for non–AIDS-defining cancers increased from 7.2% to 11.8% during 2011–2015. Cancer-attributable mortality was highest among those aged ≥60 years (952.2 per 100 000 person-years), with 19.0% of deaths attributed to non–AIDS-defining cancers. Conclusions Although cancer-attributable mortality has declined over time, it remains high and represents a growing fraction of deaths in the US HIV population. Mortality from non–AIDS-defining cancers may rise as the HIV population ages. ART access, early cancer detection, and improved cancer treatment are priorities for reducing cancer-attributable mortality.


2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 11s-11s
Author(s):  
A.Z. Shams ◽  
V. Winkler ◽  
H. Pohlabeln ◽  
V. Arndt ◽  
U. Haug

Background: Liver cancer is the second most common cause of death from cancer worldwide1. In 2013, 79,2000 new cases of liver cancer and 818,000 deaths occurred globally2,3. Chronic infection with HBV accounts for at least 50% of liver cancer globally4. In the United States (US), liver cancer constitute the ninth leading cause of cancer death. The incidence of the cancer has persistently increased in the recent decades. Universal HBV vaccination was introduced in 1992 in the US. However, incidence trends of liver cancer among US children is poorly researched or relevant studies are not up-to-date5. Aim: This study aims to explore the effect of HBV population-wide vaccination program in reducing liver cancer incidence in the vaccinated children and adolescents in the US. Methods: Liver cancer incidence data were obtained from Cancer Incidence in Five Continents (CI5) databases (volumes I to X) from International Agency for Cancer Research (IARC). Data acquisition and analysis covered available incidence data between 1978-2007 from 9 cancer registries from Surveillance, Epidemiology, and End Results Program (SEER) from the US presented in the CI5 databases. Age-specific incidence rates of liver cancer (based on 5 year age groups ie 5-9 year, 10-14 year and 15-19 years) were calculated using age and sex-disaggregated incidence and population data from the SEER cancer registries. Stata software version 14.0 (StataCorp, USA) was used to calculate age-specific incidence rates, using number of liver cancer incident cases in each age group by the number of population in the respective age group. Age-specific rates were analyzed by period of diagnosis and by birth year. Rate ratios were estimated from age-group-specific Poisson regressions. Results: A total of 140 liver cancer incident cases were registered in the 9 SEER registries between 1978 to 2007 in the US. The incidence rate of liver cancer in children 5 to 9 years of age from 1978-1982 was 0.10 per 100,000 children. The incidence increased to 0.16 for the period from 2003-2007. The same trend is seen for the age group 10-14 and 15-19 years of age. Overall, age-specific incidence rates for liver cancer increased across age groups of 5-9, 10-14 and 15-19 year in the population covered by the 9 SEER registries in the US. However, risk estimates (incidence rate ratios, resulted from age-group-specific Poisson regressions did not show statistical significant effects. Conclusion: While the global response to implement population-wide HBV vaccination program is out of question, efforts to establish processes to evaluate the effect of such programs seems to be incomparably limited. Estimating the effect of HBV vaccination will relatively improve with time as further incidence data become available eg upon publication of data from new volume of CI5 databases.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 1292-1292
Author(s):  
Philip S Rosenberg ◽  
Kimberly A Barker ◽  
William F Anderson

Abstract BACKGROUND: Multiple myeloma (MM) is the second most common hematological malignancy in the United States (US), representing 1.4% of all new cancers. MM incidence increases rapidly with age, is twice as common among African Americans versus other groups, and is a top ten cause of cancer deaths among African Americans. Although the absolute number of new MM cases per year, or MM burden, is expected to be higher in future years because of predictable changes in the demographic profile of the US, to date no study has made detailed forecasts of future MM incidence or burden by age, race/ethnicity, and sex. In this study we construct such forecasts for the period 2011 through 2034 using cancer incidence data from the National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) Program, a novel age-period-cohort (APC) forecasting model, and official projections of population sizes produced by the US Bureau of the Census. METHODS: We obtained MM case and population data from the SEER 13 Registries Database for 1993 – 2010 for all men and women, and for non-Hispanic whites, Hispanics, Blacks, and Asian and Pacific Islanders (API). To obtain stable APC estimates for each population, we aggregated single-year data into sixteen 3-year age groups (37 – 39 through 82 – 84) and six 3-year periods (1993 – 1995 through 2008 – 2010) spanning 21 partially overlapping 6-year birth cohorts centered on birth-years 1911, 1914, through 1971. Cohort effects in our APC models enabled us to make incidence forecasts allowing for different time trends in different age groups and to extrapolate incidence trends to future birth cohorts. We estimated future numbers of new cases for each sex by race/ethnic group by multiplying APC incidence rate forecasts from SEER 13 (which covers 14% of the US) by US Census population projections for the entire US for each sex and race/ethnic group. RESULTS: APC-based age incidence curves estimated from SEER13 data for incorporation into national projections reflected the contemporary epidemiology of MM: age incidence was higher among men than women in every race/ethnic group especially at ages 64 – 84 years, was highest in Blacks and lowest in API, and was similar in non-Hispanic Whites and Hispanics. In APC analyses, observed MM incidence from 1993 – 2010 was stable among men ages 37 – 63, increasing by around 0.5 percent per year among men ages 64 – 84, and stable among women in all age groups. Projected incidence for 2011 – 2034 was stable or slightly increasing in every age group. Projected MM burdens (numbers of new cases per year) were stable or slightly increasing for men and women ages 37 – 63. In contrast, large increases in the numbers of Americans ages 64 – 84 are expected to result in substantial increases in MM burden in this age group. In 2011-2013 we estimate a total of 11,200 new MM cases in men and 8,500 new cases in women. For 2032-2034 we forecast a total of 18,500 new cases in men and 13,700 new cases in women (65% and 61% increases, respectively). Among older persons ages 64 – 84, corresponding estimates are 7,300 male and 5,400 female cases in 2011 – 2013 approximately doubling to 14,100 male and 10,300 female cases in 2032-2034. Among older black men, who have the highest MM incidence and whose population is expected to increase by 4.3% per year, the projected increase in burden is 152% (from 1,210 to 3,050 cases per year). Among older Hispanic men (stable MM incidence, population increasing by 5.5% per year) the burden is expected to triple (from 460 to 1,370 cases per year). Among all older men, increases in MM burden above population growth reflect a modest increase in MM incidence. Increases in MM burden in other groups are in line with corresponding increases in population. DISCUSSION: MM incidence has been relatively stable in the US during 1993 – 2010. Our forecast is that MM incidence will continue to be quite stable during 2011 – 2032. Nonetheless, because of predictable demographic shifts in the US, the number of new MM cases per year is expected to increase by 65% in men and 61% in women between 2011-2013 and 2032-2034. Almost all of these increases will occur among older Americans ages 64 – 84. In this age group, the number of new cases overall will double, and more than double among Black and Hispanic men and women. IMPACT: Detailed forecasts quantify increasing demands for health services personnel and resources, and highlight the need for more effective MM therapies, especially for patients ages 64 – 84. Disclosures No relevant conflicts of interest to declare.


2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e12036-e12036
Author(s):  
Jigisha P. Thakkar ◽  
Bridget J. McCarthy ◽  
John L. Villano

e12036 Background: In the US, from 2004-2008, approximately 7.8% of all cancers were diagnosed and 15.2% of cancer deaths occurred in those age 85 and older. Due to the aging of the US population, a focus on the incidence of cancer in the elderly population is needed to advance knowledge on the prevention, diagnosis, and treatment of cancer in this age group. Methods: Data was retrieved from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review and from the SEER website. Data from seventeen SEER registries for the years 2000-2008 were included. Cancer sites/histologies included invasive cases only, unless otherwise noted, and rates were per 100,000. Age-specific incidence rates for meningioma were obtained from Central Brain Tumor Registry of the United States (CBTRUS) Statistical Report: NPCR (National Program of Cancer Registries) and SEER (2004-2007). Results: The overall cancer incidence rate decreases in the elderly age group. The age-specific (crude) SEER incidence rate for all cancer sites combined for those aged 85+ is 2299.65/100,000. Elderly males have a higher incidence rate as compared to elderly females (3220.7 versus 1884.9). Despite the overall decline in the incidence rate in the oldest age group, the cancer sites and/or histologies with continued increasing incidence rates after 85 years of age are: colon, bones and joints, gall bladder, Kaposi’s sarcoma, leukemia, myelodysplastic syndromes, pancreas, soft tissue including heart, vulva, vagina, and meningioma. Conclusions: Among cancer sites with increasing incidence after age 85; colon cancer has the highest incidence rate. Screening and early diagnosis for cancer in the elderly should be critically considered for colorectal cancers.


2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e18168-e18168
Author(s):  
Nishi Shah ◽  
Ana Acuna-Villaorduna ◽  
Sanjay Goel

e18168 Background: Several studies show that incidence of colorectal cancer is increasing among young individuals. However, information on incidence of early onset colon cancer by race and stage is lacking. Methods: We analyzed incidence of colon cancer using National Program of Cancer Registries database which covers 99% of the US population. We identified colon cancer using ICD-O-3 code 8000-9049, 9056-9139, 9141-9589, along with the variable for site from cecum to sigmoid colon for years 2001 to 2015. SEER*Stat was used to calculate age-adjusted rates, trends and annual percent change. Results: Age adjusted incidence rate for colon is 31.2 cases per 100,000 among the entire population. Incidence in the age group of 15-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, 80+ years is 2.4, 14.3, 39.8, 86, 165.8, 232.3 per 100,000 respectively. The distribution of colon cancer by race for age groups is listed in table. When evaluating the incidence trend in each race for early onset colon cancer, the trend shows a rise in whites for both age groups (Annual Percent Change [APC] 3.4%, 1.5% for 15-39 years, 40-49 years of age respectively, p < 0.05). The trend in blacks on the other hand shows a rise of 1.2% (p < 0.05) in 15-39 years of age and a small but statistically significant decrease in incidence in 40-49 years of 0.5% (p < 0.05). In Asian Pacific Islanders (API) and American-Indians or Alaskan Natives (AI), the trend is not significant for either age groups. In the age groups above 50 years, the trend shows a decrease in incidence of colon cancer in all races. The rise in incidence for colon cancer in 15-39 years age group appears higher in localized disease as compared to metastatic disease (6.5% vs 2.8% for localized vs distant site of disease). Conclusions: This study highlights differences in incidence of early onset colon cancer among young patients by race and stage. Although there have been more cases of early onset colon cancers in blacks, the rise in incidence is higher in whites. With colonoscopy, there has been decrease in incidence of colon cancer for patients > 50 years for all races and stages. [Table: see text]


2018 ◽  
Vol 10 (1) ◽  
Author(s):  
Kristin Baltrusaitis ◽  
Kathleen Noddin ◽  
Colleen Nguyen ◽  
Adam Crawley ◽  
John S. Brownstein ◽  
...  

ObjectiveTo estimate and compare influenza attack rates (AR) in the United States (US) using different approaches to adjust for reporting biases in participatory syndromic surveillance data.IntroductionBecause the dynamics and severity of influenza in the US vary each season, yearly estimates of disease burden in the population are essential to evaluate interventions and allocate resources. The CDC uses data from a national health-care based surveillance system and mathematical models to estimate the overall burden of disease in the general population. Over the past decade, crowd-sourced syndromic surveillance systems have emerged as a digital data source that collects health-related information in near real-time. These systems complement traditional surveillance systems by capturing individuals who do not seek medical care and allowing for a longitudinal view of illness burden. However, because not all participants report every week and participants are more likely to report when ill, the number of weekly reports is temporally and spatially inconsistent and the estimates of disease burden and incidence may be biased. In this study, we use data from Flu Near You (FNY), a participatory surveillance system based in the US and Canada1, to estimate and compare Influenza-like Illness (ILI) ARs using different approaches to adjust for reporting biases in participatory surveillance data.MethodsThis analysis uses FNY data from the 2015-16 influenza season. Four different approaches of bias adjustment were assessed. The first approach includes all FNY participants, defined as users and household members, who submitted at least one symptom report, whereas the second approach only includes FNY participants who submitted at least 10 symptom reports. The third approach includes all FNY participants who submitted at least one symptom report, but drops the first symptom report for all participants. For the first three approaches, all missing reports were assumed to be non-ILI when estimating attack rates. Finally, the fourth approach includes FNY participants who submitted at least 10 symptom reports and uses multiple imputation to account for missing reports. Age-stratified and overall estimates of ILI ARs were calculated for each of the four approaches to bias adjustment by dividing the sum of the weekly incident cases of ILI, defined as the first report of fever with cough and/or sore throat, by the population at risk at the beginning of the period.ResultsDuring the 2016-2017 influenza season, FNY received an average of 10,723 unique symptom reports per week from 46,390 registered users and their household members. For FNY, the youngest age group assessed, 5-17, had the largest ILI AR, and the ILI ARs decreased as the age group increased for all approaches. Overall, the approach that drops all first reports had the smallest ARs, whereas the approach that selects a cohort of users who submit at least 10 reports during the season and imputes the missing reports had the largest ARs. Although the influenza ARs estimated by the CDC were less than the ILI ARs estimated using FNY data for all age-groups, a similar pattern was observed across age groups, except for the 50-64 age group, which had the largest influenza AR.ConclusionsAs expected, the ARs estimated using FNY data were greater than the CDC’s influenza ARs because FNY estimates ARs of ILI and does not adjust for the probability of reporting ILI when experiencing non-flu illness. The approach of dropping the first report had the smallest ARs because during the 2015-16 influenza season the weekly percent of ILI cases that were first time reports ranged from 18-59%. This approach was developed to adjust for the potential correlation between symptom presence and willingness to join the platform. However, important information about the dynamics of disease may be lost when using this approach. The multiple imputation method was used only for individuals who submitted at least 10 reports to maintain a missing data rate below 30%. The imputation model also assumed that data were missing at random, which may not be appropriate in this case, because approximately 30% of FNY users have reported that they are more likely to report when ill. As shown in Table 1, the AR estimate depends on the bias adjustment approach. Simulation-based studies should be performed to further evaluate these methods.References1. Smolinski MS, Crawley AW, Baltrusaitis K, Chunara R, Olsen JM, Wójcik O, et al. Flu Near You: Crowdsourced Symptom Reporting Spanning 2 Influenza Seasons. Am J Public Health. 20152. Rolfes MA, Foppa IM, Garg S, Flannery B, Brammer L, Singleton JA, et al. Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths Averted by Vaccination in the United States. 2016 Dec 9 [2017 Sept 25];https://www.cdc.gov/flu/about/disease/2015-16.htm 


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 4765-4765
Author(s):  
Vivek Kumar ◽  
Taimur Sher ◽  
Prakash Vishnu ◽  
Vivek Roy ◽  
Anne M Hazen ◽  
...  

Abstract Background: The treatment of NHL has witnessed a paradigm shift over time, with targeted immunotherapy, stem cell transplant (SCT) among others. Historically, XRT was used quite frequently for the management of NHL but with advent of better systemic therapy, its utilization has changed. Trends and patterns of care for XRT use have never been formally reported. Methods: We identified patients with NHL diagnosis in the National Cancer Database (NCDB) between years 2004 and 2015. Demographic, clinical, facility level, initial treatment and outcome data were collected. The utilization of XRT in diffuse large B-cell (DLBCL) and non-DLBCL NHL were analyzed separately by univariate and multivariate analyses. To analyze the trends in the rates of XRT, we applied segmented linear regression to calculate the average annual percent change (AAPC) and 95% confidence Interval (CI) with a 'p' value. AAPC and CIs were calculated using the segmented package in R studio v1.1.49. Rest of the analyses was conducted using StataCorp version 15.1. Results: A total of 133,182 DLBCL and 204,933 non-DLBCL patients were identified. Among patients with DLBCL, 27,895 (20.9%) patients received RT. The rate of XRT declined from 25% in 2004 to 18.4% in 2015 with estimated AAPC of -0.59% (95%CI: -0.70- -0.49), p= 0.03 (Figure 1). In a subgroup analysis, a similar decline in the rate of XRT was evident across all the age groups, combined stages I and II vs stages III and IV and nodal vs extra nodal DLBCL (Table 1). Among non DLBCL, 33,369 (16.3%) patients received XRT. There was a statistically significant decline in the rate of XRT from 18.03% in 2004 to 16.3% in 2014 with an AAPC of -0.26 (95%CI: -0.38- -0.14) p <0.001 (Figure 1). On the subgroup analysis, the utilization of XRT declined across all the studied subgroups except among patients aged 80 years and above (Table 1). On multivariate analysis, several demographic, clinical and facility level factors were found to be significantly associated with XRT utilization in NHL (Table 2). In particular, older age groups, racial/ethnic minorities, advanced stages, higher Charlson comorbidity scores and diagnosis in the more recent calendar years were associated with lesser chances of receiving RT. Extranodal DLBCL had lower utilization while extranodal non-DLBCL had increased XRT utilization. Conclusion: There has been a significant decline in the utilization of XRT among patients with NHL (DLBCL and non-DLBCL) in the US since 2004, likely due to introduction of practice changing systemic therapeutics. There is still significant heterogeneity noted in practice patterns regarding utilization of XRT across the US. Having more standardized guidelines will help streamline delivery of evidence-based patient care. Disclosures Ailawadhi: Celgene: Consultancy; Janssen: Consultancy; Amgen: Consultancy; Takeda: Consultancy; Pharmacyclics: Research Funding.


2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 1514-1514
Author(s):  
Robin Robin Yabroff ◽  
Xiao-Cheng Wu ◽  
Serban Negoita ◽  
Jennifer Stevens ◽  
Linda Coyle ◽  
...  

1514 Background: The COVID-19 pandemic led to delays in medical care in the United States. We examined changes in patterns of cancer diagnosis and surgical treatment in 2020 using real-time electronic pathology report data from population-based SEER cancer registries in Georgia and Louisiana. Methods: Bi-weekly numbers, distributions, and patterns of pathology reports were compared between January 1st and December 31st in 2020 and the same period in 2019 by age group and cancer site. Results: During 2020, there were 29,905 fewer pathology reports than in 2019, representing a 10.2% decline. Absolute declines were greatest among adults aged ≥50 years (N=23,065); percentage declines were greatest among children and young adults ≤18 years (38.3%). By cancer site, percentage declines were greatest for lung cancer (17.4%), followed by colorectal (12.0%), breast (9.0%) and prostate (5.8%) cancers. Biweekly reports were statistically significantly lower in 2020 than in 2019 from late March through the end of December in most biweekly periods. The nadir was the month of April 2020 – the number of reports was at least 40% lower than in April 2019. The number of reports in 2020 compared with 2019 also declined sharply in early November (26.8%) and late December (32.0%). Numbers of reports in 2020 never consistently exceeded those in 2019 after the first decline. Patterns were similar by cancer site, with variation in magnitude and duration of declines. Conclusions: Significant declines in cancer pathology reports from population-based registries during 2020 suggest substantial delays in screening, evaluation of signs and symptoms, diagnosis, and treatment services for cancers with effective screening tests as well as in cancer sites and age groups without effective screening tests as an indirect result of the COVID-19 pandemic. Ongoing evaluation will be critical for informing public health efforts to minimize any lasting adverse effects of the pandemic on cancer screening, diagnosis, treatment, and survival.[Table: see text]


2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 2099-2099
Author(s):  
John L. Villano ◽  
Stephen Todd Anderson ◽  
Therese A. Dolecek

2099 Background: Although meningioma is the most common tumor in the central nervous system (CNS), the incidence, epidemiology, and clinical outcomes have historically been poorly defined. Our analysis follows the implementation of Public Law 107–260, the Benign Brain Tumor Cancer Registries Act mandating collection of non-malignant meningiomas. Methods: Surveillance Epidemiology End Results Program (SEER) 18 registries research data on cases diagnosed during 2004-2009 with meningioma (ICD-O-3 histology codes 9530-9534 & 9537-9539) in brain or CNS primary site (C70.0-72.9, 75.1-75.3 ) were analyzed. Population-based statistics were generated using SEER*Stat 8.0.1 software. Results: A total of 35,302 cases (34,718 non-malignant; 584 malignant) were available providing a rate of 7.18/100,000, with meningioma, NOS (9530/0) the most common histology. Rates increased with age (0.13/100,000, 0-19 years; 37.78/100,000, 75+ years). The annual percentage change in incidence rates showed a statistically significant increase of 2.57% over 2004-2009. Significant increases were also observed for males, females, whites, blacks, non-Hispanics, and older age groups. The gender ratio M:F was 0.35 in the 0-49 age group and 0.48 in the 50+ age. Primary site location included cerebral meninges (83%) with almost 5% in the spinal meninges. 51% of cases were diagnosed pathologically versus imaging. However, diagnosis among 85% of spinal cases was surgically based. Older age and females were less likely to have a surgical diagnosis. 3.4% received radiation therapy (RT) with 97% receiving RT following surgery. For grade III or malignant cases, 22% received RT, and in grade 1 and 2 nearly 97% of cases did not receive RT, with older age groups less likely to receive RT. Overall survival was high, except for grade 3 or malignant cases where 5 year relative survival was 61.7%. Conclusions: Our analysis following Public Law 107–260 demonstrates an increasing incidence of meningiomas and provides new information, including a decrease in the gender difference with age. Clinical diagnosis is common and higher in women and older adults. Use of RT is low, even in malignant meningiomas, and employed following surgery. These observations were similar for white and black cases.


Sign in / Sign up

Export Citation Format

Share Document